Trial Profile
Efficacy of moxofloxacin-containing treatment regimen in patients with refractory mycobacterium avium complex lung disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2014
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary) ; Antibacterials
- Indications Mycobacterium avium complex infections
- Focus Therapeutic Use
- 29 Sep 2014 New trial record